Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib-Reference-Cited by-同舟云学术

Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib

Published:2024-02 Issue: Volume:194 Page:104243
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Russo Giuseppe Lo,Bironzo Paolo,Bennati Chiara,Bonanno Laura,Catino Annamaria,Metro Giulio,Petrini Iacopo,Russano Marco,Passaro Antonio^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference65 articles.

1. The next target for NSCLC: let it be “RET;Ahn;J. Thoracic Oncol,2020

2. RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion;Aldea;J. Thorac. Oncol.,2023

3. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers;Ali;Arch. Pharm. Res.,2022

4. RET rearrangement as a predictor of unresponsiveness to immunotherapy in non-small cell lung cancer: report of two cases with review of the literature;Baglivo;Oncol. Ther.,2020

5. Global epidemiology of lung cancer;Barta;Ann. Glob. Health,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determination of Pralsetinib in Human Plasma and Cerebrospinal Fluid for Therapeutic Drug Monitoring by Ultra-performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS);Anti-Cancer Agents in Medicinal Chemistry;2024-07